This article was originally published by Gerard T. Vondeling, Qi Cao, Maarten J. Postma, and Mark H. Rozenbaum in Applied Health Economics and Health Policy (2018) pp.1-8 under a Creative Commons Attribution-NonCommercial…
Former Congressman Henry Waxman was recently interviewed for the Clause 8 podcast about how he worked together with Sen. Orrin Hatch to pass the Hatch-Waxman Act and its aftermath. Congressman…
Annual Drug Patent Expirations for JAKAFI Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are seven patents…
This paper was originally published by Witold Jamróz, Joanna Szafraniec, Mateusz Kurek, and Renata Jachowicz in Pharmaceutical Research September 2018, 35:176 under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). Abstract Growing demand…
There are more than 7,000 diseases that are considered “rare,” that is, affecting fewer than 200,000 Americans. Yet around one in ten Americans lives with at least one of these…
A few years ago, there was much talk of the “patent cliff” facing blockbuster drugs like Lipitor and other huge name-brand drugs. The “patent cliff” may have spelled the end…
This article was originally published by Li Du in BMC Medical Ethics 2018 19:29 under a creative commons license. Abstract Background The patenting of human genes has been the subject…
Drug development is one of the world’s most high-risk / high-reward industries, with the vast majority of drugs created never making it to market. Of those that do make it…
Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly…
Artificial intelligence (AI) is the development within computer systems of the ability to perform tasks that have traditionally required human intelligence. Examples of AI applications include visual perception, speech recognition,…